(Q33533628)

English

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Christos J Petropoulos

14

object named as

Christos Petropoulos

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Norikazu Masuda

11

object named as

Norikazu Masuda

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

10

object named as

Hiroji Iwata

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1

object named as

Masakazu Toi

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

4

object named as

Shigehira Saji

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

author name string

Jeff Sperinde

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Weidong Huang

3

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

John Winslow

5

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Xueguang Jin

6

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Yuping Tan

7

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Shinji Ohno

8

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Seigo Nakamura

9

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Kenjiro Aogi

12

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Satoshi Morita

13

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Michael Bates

15

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

language of work or name

0 references

publication date

23 February 2010

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-10-56

0 references

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

The distinctive nature of HER2-positive breast cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

Untangling the ErbB signalling network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837013

21 June 2018

Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-56

21 January 2018

A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-56

21 January 2018

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-56

21 January 2018

Breast cancer--loss of PTEN predicts resistance to treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20178580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20178580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab in the treatment of breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20178580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20178580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-10-56

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33533628&oldid=1756367452"